Clinical Trial Update: Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating ixabepilone in patients with metastatic or recurrent head and neck squamous cell carcinoma; the study has completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Ixabepilone (ixabepilone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Status: COMPLETED